Alendronate-Related Femoral Fracture in a premenopausal glucocorticoid treated patient
|
Maryam Mobini |
Department of Rheumatology, Mazandaran University of Medical Sciences, Sari, Iran. , mmobini50@yahoo.com |
|
Abstract: (28836 Views) |
Abstract
Background: Alendronate is a bisphosphonate that is approved to reduce bone loss in glucocorticoid treated patients. In this paper, we present a case of femoral fracture following the use of Alendronate.
Case presentation: A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendronate 70 mg/week for 3 years. Despite improvement of bone density, she experienced a low truama femoral shaft fracture.
Conclusion: This case shows a rare complication of treatment by alendronate. It may be needed to evaluate patients with long term usage of bisphosphonates for cortical thickness. |
|
Keywords: Alendronate, Bisphosphonate, Fracture, Prednisolon, Hemolytic anemia |
|
Full-Text [PDF 111 kb]
(3061 Downloads)
|
Type of Study: Original Article |
Subject:
Infectious Diseases Received: 2013/12/21 | Accepted: 2013/12/21 | Published: 2013/12/21
|
|
|
|